AU Patent

AU2012201288C1 — Novel pharmaceutical composition

Assigned to Novartis AG · Expires 2025-05-01 · 1y expired

What this patent protects

C:\NRPoflbl\DCC\KXG\41MIP.97 .DOC-2/I11/2012 ABSTRACT Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4 dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazine]-2' hydroxy-[,'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)(eltromb…

USPTO Abstract

C:\NRPoflbl\DCC\KXG\41MIP.97 .DOC-2/I11/2012 ABSTRACT Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4 dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazine]-2' hydroxy-[,'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)(eltrombopag olamine) and processes for preparing the same.

Drugs covered by this patent

eltrombopag-olamine (ELTROMBOPAG OLAMINE)

Patent Metadata

Patent number: AU2012201288C1
Jurisdiction: AU
Classification: —
Expires: 2025-05-01
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.